In focus

Global Market Perspective Q1 2021: economic and asset allocation views

News that a Covid-19 vaccine is on its way has provided a boost to the
outlook for the world economy, and spurred a significant rally in risk assets.

Over the fourth quarter, the more cyclical equity markets of Europe and emerging markets outperformed. However, the return fortunes of bonds were more mixed. There were positive gains in credit and emerging market sovereign bonds. But government bond returns were broadly flat and negative for US Treasuries.

We have upgraded our global growth outlook for the world economy. In the near-term, the return of lockdown restrictions has weakened activity in the fourth quarter, and may do so in the first quarter of 2021 if restrictions remain. But in the second half of the year, we expect global growth to be strong due to the vaccine coming on line.

Against this backdrop, inflation remains relatively contained in our forecast allowing central banks to keep monetary policy loose.

The greatest risks to our central macro view are a “taper tantrum 2”, as markets react adversely to a moderation in quantitative easing (QE), and a stronger recovery particularly now the Democrats control Congress and can expand US fiscal policy more aggressively. Another risk is a weaker dollar.

From an asset allocation perspective, we remain positive on equities but have trimmed positioning in high yield (HY) debt. Equity valuations continue to be supported by depressed bond yields. However, return opportunities in credit have been reduced given further tightening in spread levels.

We remain positive on corporate investment grade (IG) bonds due to continued support buying by the central banks. Within equities, we have kept our positive exposure to emerging equities and increased positioning in Japan, as there is evidence of a strong industrial recovery in Asia.

In comparison, we have turned negative on duration. We believe that government bonds, particularly German Bunds, offer limited protection against the prospect of a growth disappointment.

Please find this quarter's full document below.

Read the full report

Global market perspective - Q1 2021 16 pages | 4,532 kb


Important Information: This communication is marketing material. The views and opinions contained herein are those of the author(s) on this page, and may not necessarily represent views expressed or reflected in other Schroders communications, strategies or funds. This material is intended to be for information purposes only and is not intended as promotional material in any respect. The material is not intended as an offer or solicitation for the purchase or sale of any financial instrument. It is not intended to provide and should not be relied on for accounting, legal or tax advice, or investment recommendations. Reliance should not be placed on the views and information in this document when taking individual investment and/or strategic decisions. Past performance is not a reliable indicator of future results. The value of an investment can go down as well as up and is not guaranteed. All investments involve risks including the risk of possible loss of principal. Information herein is believed to be reliable but Schroders does not warrant its completeness or accuracy. Some information quoted was obtained from external sources we consider to be reliable. No responsibility can be accepted for errors of fact obtained from third parties, and this data may change with market conditions. This does not exclude any duty or liability that Schroders has to its customers under any regulatory system. Regions/ sectors shown for illustrative purposes only and should not be viewed as a recommendation to buy/sell. The opinions in this material include some forecasted views. We believe we are basing our expectations and beliefs on reasonable assumptions within the bounds of what we currently know. However, there is no guarantee than any forecasts or opinions will be realised. These views and opinions may change. The content is issued by Schroder Investment Management Limited, 1 London Wall Place, London EC2Y 5AU. Registered No. 1893220 England. Authorised and regulated by the Financial Conduct Authority.